Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Angus

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
The Journal of Biological Chemistry|February 25, 1991
Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous proteinP R Langer-Safer, T J Ahern, L B Angus, et al.
International Journal of Cancer|August 7, 1997
Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 proteinH Bryden, J MacKenzie, L Andrew, et al.
European Journal of Haematology. Supplementum|August 7, 2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacyS J Proctor, P R Taylor, B Angus, et al.
Histopathology|February 15, 2000
Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphomaP Watson, K M Wood, A Lodge, et al.
Leukemia & Lymphoma|October 24, 2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacyG H Jackson, B Angus, P J Carey, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
The Journal of Biological Chemistry|February 25, 1991
Replacement of finger and growth factor domains of tissue plasminogen activator with plasminogen kringle 1. Biochemical and pharmacological characterization of a novel chimera containing a high affinity fibrin-binding domain linked to a heterologous proteinP R Langer-Safer, T J Ahern, L B Angus, et al.
International Journal of Cancer|August 7, 1997
Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 proteinH Bryden, J MacKenzie, L Andrew, et al.
European Journal of Haematology. Supplementum|August 7, 2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacyS J Proctor, P R Taylor, B Angus, et al.
Histopathology|February 15, 2000
Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphomaP Watson, K M Wood, A Lodge, et al.
Leukemia & Lymphoma|October 24, 2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacyG H Jackson, B Angus, P J Carey, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Pageof 17